The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Open accessAbstract
Despite the recent advances in controlling some viral pathogens, most viral infections still lack specific treatment. Indeed, the need for effective therapeutic strategies to combat ‘old’, emergent, and re-emergent viruses is not paralleled by the approval of new antivirals. In the past years, drug repurposing combined with innovative approaches for drug validation, and with appropriate animal models, significantly contributed to the identification of new antiviral molecules and targets for therapeutic intervention. In this review, we describe the main strategies of drug repurposing in antiviral discovery, discuss the most promising candidates that could be repurposed to treat viral infections, and analyze the possible caveats of this trendy strategy of drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W.-K., Qian, X., TCW, J., Kouznetsova, J., Ogden, S. C., Hammack, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4184 · Cited by 641
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, J.-F. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.014 · Cited by 556
Zika virus cell tropism in the developing human brain and inhibition by azithromycin
Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., Mancia Leon, W. R., Krencik, R., Ullian, E. M., Spatazza, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618029113 · Cited by 506
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.004 · Cited by 497
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 436
Zika virus: history of a newly emerging arbovirus
Wikan, N., & Smith, D. R. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30010-x · Cited by 429
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection
Johansen, L. M., Brannan, J. M., Delos, S. E., Shoemaker, C. J., Stossel, A., Lear, C., Hoffstrom, B. G., DeWald, L. E., Schornberg, K. L., Scully, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005471 · Cited by 332
Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models
Delvecchio, R., Higa, L., Pezzuto, P., Valadão, A., Garcez, P., Monteiro, F., Loiola, E., Dias, A., Silva, F., Aliota, M., et al. (2016) · Viruses · doi:10.3390/v8120322 · Cited by 279
Zhou, T., Tan, L., Cederquist, G. Y., Fan, Y., Hartley, B. J., Mukherjee, S., Tomishima, M., Brennand, K. J., Zhang, Q., Schwartz, R. E., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.06.017 · Cited by 263
Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein
Strating, J. R. P. M., van der Linden, L., Albulescu, L., Bigay, J., Arita, M., Delang, L., Leyssen, P., van der Schaar, H. M., Lanke, K. H. W., Thibaut, H. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.054 · Cited by 258
Coleman, C. M., Sisk, J. M., Mingo, R. M., Nelson, E. A., White, J. M., & Frieman, M. B. (2016) · Journal of Virology · doi:10.1128/jvi.01429-16 · Cited by 257
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., & Rossignol, J.-F. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70717-0 · Cited by 251
A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
Madrid, P. B., Chopra, S., Manger, I. D., Gilfillan, L., Keepers, T. R., Shurtleff, A. C., Green, C. E., Iyer, L. V., Dilks, H. H., Davey, R. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060579 · Cited by 247
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Sacramento, C. Q., de Melo, G. R., de Freitas, C. S., Rocha, N., Hoelz, L. V. B., Miranda, M., Fintelman-Rodrigues, N., Marttorelli, A., Ferreira, A. C., Barbosa-Lima, G., et al. (2017) · Scientific Reports · doi:10.1038/srep40920 · Cited by 247
Drug repurposing screens and synergistic drug‐combinations for infectious diseases
Zheng, W., Sun, W., & Simeonov, A. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13895 · Cited by 247
The FDA-approved drug sofosbuvir inhibits Zika virus infection
Bullard-Feibelman, K. M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M. S., & Geiss, B. J. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.023 · Cited by 246
Johansen, L. M., DeWald, L. E., Shoemaker, C. J., Hoffstrom, B. G., Lear-Rooney, C. M., Stossel, A., Nelson, E., Delos, S. E., Simmons, J. A., Grenier, J. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5597 · Cited by 236
Kouznetsova, J., Sun, W., Martínez-Romero, C., Tawa, G., Shinn, P., Chen, C. Z., Schimmer, A., Sanderson, P., McKew, J. C., Zheng, W., et al. (2014) · Emerging Microbes & Infections · doi:10.1038/emi.2014.88 · Cited by 227
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Strittmatter, S. M. (2014) · Nature Medicine · doi:10.1038/nm.3595 · Cited by 222
Li, Z., Brecher, M., Deng, Y.-Q., Zhang, J., Sakamuru, S., Liu, B., Huang, R., Koetzner, C. A., Allen, C. A., Jones, S. A., et al. (2017) · Cell Research · doi:10.1038/cr.2017.88 · Cited by 208
Dyall, J., Gross, R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Hensley, L. E., Frieman, M. B., & Jahrling, P. B. (2017) · Drugs · doi:10.1007/s40265-017-0830-1 · Cited by 199
Applications of chemogenomic library screening in drug discovery
Jones, L. H., & Bunnage, M. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.244 · Cited by 188
Antiviral strategies against influenza virus: towards new therapeutic approaches
Loregian, A., Mercorelli, B., Nannetti, G., Compagnin, C., & Palù, G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1615-2 · Cited by 184
Self-citationTaylor, R., Kotian, P., Warren, T., Panchal, R., Bavari, S., Julander, J., Dobo, S., Rose, A., El-Kattan, Y., Taubenheim, B., et al. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.04.002 · Cited by 177
Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus
Rausch, K., Hackett, B. A., Weinbren, N. L., Reeder, S. M., Sadovsky, Y., Hunter, C. A., Schultz, D. C., Coyne, C. B., & Cherry, S. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.068 · Cited by 172
Lejal, N., Tarus, B., Bouguyon, E., Chenavas, S., Bertho, N., Delmas, B., Ruigrok, R. W. H., Primo, C. D., & Slama‐Schwok, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02335-12 · Cited by 150
He, S., Lin, B., Chu, V., Hu, Z., Hu, X., Xiao, J., Wang, A. Q., Schweitzer, C. J., Li, Q., Imamura, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010286 · Cited by 148
Hung, I. F., To, K. K., Chan, J. F., Cheng, V. C., Liu, K. S. H., Tam, A. R., Chan, T.-C., Zhang, J., Li, P., Wong, T.-L., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.11.012 · Cited by 128
Kamiyama, N., Soma, R., Hidano, S., Watanabe, K., Umekita, H., Fukuda, C., Noguchi, K., Gendo, Y., Ozaki, T., Sonoda, A., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.08.007 · Cited by 126
Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis
Shiryaev, S. A., Mesci, P., Pinto, A., Fernandes, I. R., Sheets, N., Shresta, S., Farhy, C., Huang, C., Strongin, A. Y., Muotri, A. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15467-6 · Cited by 125
Adcock, R. S., Chu, Y.-K., Golden, J. E., & Chung, D.-H. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.018 · Cited by 122
Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain
Nadal, M., Mas, P. J., Blanco, A. G., Arnan, C., Solà, M., Hart, D. J., & Coll, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007144107 · Cited by 118
Synergistic drug combination effectively blocks Ebola virus infection
Sun, W., He, S., Martínez‐Romero, C., Kouznetsova, J., Tawa, G. J., Xu, M., Shinn, P., Fisher, E. G., Long, Y., Motabar, O., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.017 · Cited by 99
Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus
Balasubramanian, A., TERAMOTO, T., Kulkarni, A. A., Bhattacharjee, A. K., & Padmanabhan, R. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.015 · Cited by 90
Costa, V. V., Sarto, J. L. D., Rocha, R. D. P. F., da Silva, F. R., Doria, J. G., Olmo, I. G., Marques, R. E., Queiroz‐Junior, C. M., Foureaux, G., Araújo, J. M. S., et al. (2017) · mBio · doi:10.1128/mbio.00350-17 · Cited by 89
de Wilde, A. H., Falzarano, D., Zevenhoven-Dobbe, J. C., Beugeling, C., Fett, C., Martellaro, C., Posthuma, C. C., Feldmann, H., Perlman, S. M., & Snijder, E. J. (2016) · Virus Research · doi:10.1016/j.virusres.2016.11.011 · Cited by 82
Blocking Zika virus vertical transmission
Mesci, P., Macia, Á., Moore, S. M., Shiryaev, S. A., Pinto, A., Huang, C., Tejwani, L., Fernandes, I. R., Suarez, N. A., Kolar, M. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19526-4 · Cited by 81
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 80
McKimm‐Breschkin, J. L., Jiang, S., Hui, D. S. C., Beigel, J. H., Govorkova, E. A., & Lee, N. L. S. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.013 · Cited by 80
Teicoplanin inhibits Ebola pseudovirus infection in cell culture
Wang, Y., Cui, R., Li, G., Gao, Q., Yuan, S., Altmeyer, R. M., & Zou, G. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.11.003 · Cited by 77
Repurposing of Prochlorperazine for Use Against Dengue Virus Infection
Simanjuntak, Y., Liang, J., Lee, Y.-L., & Lin, Y. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu377 · Cited by 75
Fighting viruses with antibiotics: an overlooked path
Colson, P., & Raoult, D. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.07.004 · Cited by 71
Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus
Mukhopadhyay, R., Roy, S., Venkatadri, R., Su, Y., Ye, W., Barnaeva, E. S., Griner, L. A. M., Southall, N. T., Hu, X., Wang, A. Q., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005717 · Cited by 66
Salata, C., Baritussio, A., Munegato, D., Calistri, A., Ha, H. R., Bigler, L., Fabris, F., Parolin, C., Palù, G., & Mirazimi, A. (2015) · Pathogens and Disease · doi:10.1093/femspd/ftv032 · Cited by 59
Self-citationHuman Cytomegalovirus Inhibition by Cardiac Glycosides: Evidence for Involvement of the hERG Gene
Kapoor, A., Cai, H., Forman, M., He, R., Shamay, M., & Arav‐Boger, R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00898-12 · Cited by 56
Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
Sweiti, H., Ekwunife, O. I., Jaschinski, T., & Lhachimi, S. K. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.01.007 · Cited by 53
Mercorelli, B., Luganini, A., Nannetti, G., Tabarrini, O., Palù, G., Gribaudo, G., & Loregian, A. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.012 · Cited by 48
Self-citationEarly inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives
Mercorelli, B., Lembo, D., Palù, G., & Loregian, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.007 · Cited by 46
Self-citationHampson, L., Maranga, I. O., Masinde, M., Oliver, A. W., Batman, G., He, X. T., Desai, M., Okemwa, P., Stringfellow, H. F., Martin‐Hirsch, P. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147917 · Cited by 46
Pharmacological intervention for dengue virus infection
Lai, J., Lin, Y., & Hsieh, S.-L. E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.005 · Cited by 42
Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals
Arend, K. C., Lenarcic, E. M., Vincent, H. A., Rashid, N. U., Lazear, E., McDonald, I. M., Gilbert, T. S. K., East, M. P., Herring, L. E., Johnson, G. L., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.065375 · Cited by 33
Hu, Y., Zhang, J., Musharrafieh, R. G., Ma, C., Hau, R. K., & Wang, J. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.07.016 · Cited by 31
Ponroy, N., Taveira, A., Mueller, N. J., & Millard, A. (2014) · Journal of Medical Virology · doi:10.1002/jmv.23998 · Cited by 30
How academic labs can approach the drug discovery process as a way to synergize with big pharma
Loregian, A., & Palù, G. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.03.006 · Cited by 30
Self-citationDrug Repurposing Identifies Inhibitors of Oseltamivir‐Resistant Influenza Viruses
Bao, J., Marathe, B. M., Govorkova, E. A., & Zheng, J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511361 · Cited by 28
Mercorelli, B., Luganini, A., Celegato, M., Palù, G., Gribaudo, G., & Loregian, A. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.014 · Cited by 24
Self-citationDroebner, K., Haasbach, E., Dudek, S. E., Scheuch, G., Nocker, K., Canisius, S., Ehrhardt, C., von Degenfeld, G., Ludwig, S., & Planz, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02130 · Cited by 23
Identification of FDA‐approved drugs that target hepatitis B virus transcription
van de Klundert, M. A. A., Zaaijer, H. L., & Kootstra, N. A. (2015) · Journal of Viral Hepatitis · doi:10.1111/jvh.12479 · Cited by 22
Cited by
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
Clinical trials on drug repositioning for COVID-19 treatment
Rosa, S. G. V., & Santos, W. C. (2020) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2020.40 · Cited by 420
Muralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1752802 · Cited by 415
Touret, F., Gilles, M., Barral, K., Nougairède, A., van Helden, J., Decroly, E., de Lamballerie, X., & Coutard, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-70143-6 · Cited by 393
Metadata
- Authors
- Mercorelli, B., Palù, G., & Loregian, A.
- Venue
- Trends in Microbiology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 26
- Issue
- 10
- Pages
- 865-876
- ISSN
- 0966-842X (ISSN-L)
- OpenAlex
- W2800221771
- Cited by
- 264
- References
- 67
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.